760 related articles for article (PubMed ID: 15065696)
21. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
22. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
Tikkanen I; Johnston CI
Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive therapy in the presence of proteinuria.
Sarafidis PA; Khosla N; Bakris GL
Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
[TBL] [Abstract][Full Text] [Related]
25. The role of calcium antagonists in patients with chronic renal failure.
Rahn KH
Pediatr Nephrol; 2005 Sep; 20(9):1208-13. PubMed ID: 15971071
[TBL] [Abstract][Full Text] [Related]
26. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
García de Vinuesa S; Luño J; Gómez-Campderá F; Ridao N; Sánchez M; Dall'Anese C; Valderrábano F
Nephrol Dial Transplant; 2001; 16 Suppl 1():78-81. PubMed ID: 11369828
[TBL] [Abstract][Full Text] [Related]
27. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
Boner G
Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
[TBL] [Abstract][Full Text] [Related]
28. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
Kalaitzidis RG; Bakris GL
Curr Opin Nephrol Hypertens; 2009 Sep; 18(5):386-91. PubMed ID: 19561494
[TBL] [Abstract][Full Text] [Related]
29. Current recommendations for the treatment of hypertension: are they still valid?
Moser M
J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Omae K; Ogawa T; Nitta K
Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
Kunz R; Friedrich C; Wolbers M; Mann JF
Ann Intern Med; 2008 Jan; 148(1):30-48. PubMed ID: 17984482
[TBL] [Abstract][Full Text] [Related]
32. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
[TBL] [Abstract][Full Text] [Related]
33. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
34. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic management of diabetic nephropathy.
Vivian EM; Rubinstein GB
Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
[TBL] [Abstract][Full Text] [Related]
36. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
[TBL] [Abstract][Full Text] [Related]
37. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
Wolf G; Ritz E
Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
[TBL] [Abstract][Full Text] [Related]
40. The renoprotective effect of combined antihypertensive drugs.
Del Vecchio L; Locatelli F
J Nephrol; 2001; 14(1):7-14. PubMed ID: 11281347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
